The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
NCT Number: NCT02472457
The primary objective of this study is to determine whether pediatric Crohn Disease (CD) patients in long-standing remission remain in remission longer after stopping medications if they follow the Crohn's Disease Exclusion Diet (CDED). The hypothesis is that subjects on the CDED will have longer time-to-relapse as opposed to those on an unrestricted diet.
Looking for future studies?
Notify Me10 year–21 year
All sexes
Interventional
Not applicable
Philadelphia, Pennsylvania, 19104, United States
Crohn disease (CD) is an idiopathic, chronic, relapsing and remitting inflammatory condition of the gastrointestinal tract with a high risk for complications and need for surgical interventions, particularly in children. Immunomodulators and biologic therapies are effective at inducing and maintaining remission in pediatric CD, yet there is no proven strategy for reducing exposure to medications once sustained remission has been achieved. Diet has been proven to impact disease activity in CD and may allow for sustained drug-free remission. The primary objective of this study is to determine whether pediatric CD patients in long-standing remission remain in remission longer after stopping medications if they follow the Crohn's Disease Exclusion Diet (CDED). The hypothesis is that subjects on the CDED will have longer time-to-relapse as opposed to those on an unrestricted diet.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The CDED is divided into 4 stages: 0-6 weeks induction phase, weeks 7-12 step down phase, weeks 13-24 maintenance phase I, and weeks 25-52 maintenance phase II.
This diet contains no restrictions.
Other names: Placebo
Time frame: At 52 weeks following enrollment
Remission defined by the Pediatric Crohn Disease Activity Index, C-reactive protein, and stool calprotectin
Time frame: Up to 104 weeks
Remission defined by the Pediatric Crohn Disease Activity Index, C-reactive protein, and stool calprotectin
Time frame: 6 weeks
Change in the microbial composition of the stool, mouth and rectum from baseline to 6 weeks
Time frame: 52 weeks
Change in the microbial composition of the stool, mouth and rectum from baseline to 52 weeks
Time frame: Up to 52 weeks
Using modified Medication Adherence Rating Scale (MARS) questionnaire
Children's Hospital of Philadelphia
Other
Biologic and Immunomodulator Withdrawal in Pediatric Crohn Disease With Deep Clinical Remission Using the Crohn Disease Exclusion Diet
Acronym: CEASE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04673357
Crohn Disease, Digestive System Diseases
Wilmington, Delaware, United States
View Trial DetailsNCT05013905
Crohn Disease, Digestive System Diseases
Los Angeles, California, United States
View Trial DetailsNCT06094608
Colitis, Colitis, Ulcerative
Ann Arbor, Michigan, United States
View Trial DetailsNCT04245215
Crohn Disease, Digestive System Diseases
Zaventem, Belgium
View Trial Details